Abstract
Interferons (IFNs) are a subclass of lymphocyte-released cytokines that interfere with intracellular viral replication. These drugs are classified into three groups: IFN type 1 (IFN-α, IFN-β, and IFN-ω), IFN type 2 (IFN-γ), and IFN type 3 (IFN-λ). Despite numerous trials, IFN therapy has yet to conclusively demonstrate superiority in the treatment of various pulmonary diseases. In addition to the FDA-approved and ongoing investigational uses for IFN therapy, there is a debate regarding the appropriate dosage of these agents. A retrospective literature review is moving experts towards low-dose therapies in nearly every application of IFN therapy. It is speculated that known and unknown toxicity may limit the beneficial effects of IFN therapy.
Keywords: Asthma, idiopathic pulmonary fibrosis, influenza, interferon.
Current Respiratory Medicine Reviews
Title:The Use of Interferons in Respiratory Diseases
Volume: 9 Issue: 5
Author(s): Ori-Michael J. Benhamou, Miriam Jacobs, Jonathan Drew, Shahar Geva, Maor Waldman and Or Kalchiem-Dekel
Affiliation:
Keywords: Asthma, idiopathic pulmonary fibrosis, influenza, interferon.
Abstract: Interferons (IFNs) are a subclass of lymphocyte-released cytokines that interfere with intracellular viral replication. These drugs are classified into three groups: IFN type 1 (IFN-α, IFN-β, and IFN-ω), IFN type 2 (IFN-γ), and IFN type 3 (IFN-λ). Despite numerous trials, IFN therapy has yet to conclusively demonstrate superiority in the treatment of various pulmonary diseases. In addition to the FDA-approved and ongoing investigational uses for IFN therapy, there is a debate regarding the appropriate dosage of these agents. A retrospective literature review is moving experts towards low-dose therapies in nearly every application of IFN therapy. It is speculated that known and unknown toxicity may limit the beneficial effects of IFN therapy.
Export Options
About this article
Cite this article as:
Benhamou J. Ori-Michael, Jacobs Miriam, Drew Jonathan, Geva Shahar, Waldman Maor and Kalchiem-Dekel Or, The Use of Interferons in Respiratory Diseases, Current Respiratory Medicine Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/1573398X10666140520004706
DOI https://dx.doi.org/10.2174/1573398X10666140520004706 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review
Inflammation & Allergy - Drug Targets (Discontinued) Update on the Molecular Genetic Studies of Behcets Disease
Current Rheumatology Reviews EDITORIAL (Thematic Issue: Serpins as Therapeutics – A Potential Biologic Source for Unique Protein-based Therapeutics)
Cardiovascular & Hematological Disorders-Drug Targets Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Potential of Non-Coding RNAs and TLR Signalling Pathways in Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties
Endocrine, Metabolic & Immune Disorders - Drug Targets Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety A Review on Natural Products for Controlling Type 2 Diabetes with an Emphasis on their Mechanisms of Actions
Current Diabetes Reviews Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry The Role of Autophagy in Rheumatic Disease
Current Drug Targets Lesson from the Pandemic: People should Always Stay Physically Active
Current Cardiology Reviews Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry The Role of Cytokines in T Help Responses to Viruses
Current Immunology Reviews (Discontinued) Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Imaging Features of Thoracic Manifestations of Behçet’s Disease: Beyond Pulmonary Artery Involvement
Current Medical Imaging A New Biomarker with High Outcome Prediction in IgA Nephropathy
Recent Patents on Biomarkers